

Annaliesa S Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5464919/publications.pdf>

Version: 2024-02-01

91
papers

5,502
citations

81900

39
h-index

88630

70
g-index

95
all docs

95
docs citations

95
times ranked

5284
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	3.3	14
2	Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 101-111.	4.7	76
3	Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. <i>Expert Review of Vaccines</i> , 2022, 21, 753-769.	4.4	2
4	Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 263-274.	9.1	70
5	Performance of a Four-Antigen <i>Staphylococcus aureus</i> Vaccine in Preclinical Models of Invasive <i>S. aureus</i> Disease. <i>Microorganisms</i> , 2021, 9, 177.	3.6	17
6	The Role of Vaccines in Combating Antimicrobial Resistance. <i>Sustainable Agriculture Reviews</i> , 2021, , 347-430.	1.1	3
7	A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. <i>Journal of Virology</i> , 2021, 95, .	3.4	94
8	The impact of human vaccines on bacterial antimicrobial resistance. A review. <i>Environmental Chemistry Letters</i> , 2021, 19, 4031-4062.	16.2	21
9	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. <i>Nature Communications</i> , 2021, 12, 6055.	12.8	215
10	An oral SARS-CoV-2 M ^{pro} inhibitor clinical candidate for the treatment of COVID-19. <i>Science</i> , 2021, 374, 1586-1593.	12.6	1,074
11	Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. <i>Vaccine</i> , 2020, 38, 1778-1786.	3.8	22
12	Commentary: Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates. <i>Frontiers in Microbiology</i> , 2020, 11, 538209.	3.5	0
13	MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. <i>Infectious Diseases and Therapy</i> , 2020, 9, 641-656.	4.0	6
14	Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics. <i>Cell Host and Microbe</i> , 2020, 28, 638-645.	11.0	30
15	Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz532.	0.9	10
16	Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. <i>Npj Vaccines</i> , 2020, 5, 8.	6.0	9
17	Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). <i>Vaccine</i> , 2020, 38, 2026-2033.	3.8	6
18	Vaccination against Nosocomial Infections in Elderly Adults. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 193-217.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Immunofluorescence Microscopy for the Detection of Surface Antigens in Methicillin Resistant <i>Staphylococcus aureus</i> (MRSA). <i>Methods in Molecular Biology</i> , 2020, 2069, 47-58.	0.9	1
20	<i>S. aureus</i> colonization in healthy Australian adults receiving an investigational <i>S. aureus</i> 3-antigen vaccine. <i>Journal of Infection</i> , 2019, 79, 582-592.	3.3	3
21	Distribution of <i>Neisseria meningitidis</i> serogroup b (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009–2014, prior to NmB vaccine licensure. <i>Journal of Infection</i> , 2019, 79, 426-434.	3.3	8
22	Flow Cytometric Assays to Quantify fHbp Expression and Detect Serotype Specific Capsular Polysaccharides on <i>Neisseria meningitidis</i> . <i>Methods in Molecular Biology</i> , 2019, 1969, 217-236.	0.9	1
23	A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization. <i>Journal of Infectious Diseases</i> , 2019, 220, 105-115.	4.0	67
24	Molecular epidemiology and expression of capsular polysaccharides in <i>Staphylococcus aureus</i> clinical isolates in the United States. <i>PLoS ONE</i> , 2019, 14, e0208356.	2.5	33
25	The role of vaccines in preventing bacterial antimicrobial resistance. <i>Nature Medicine</i> , 2018, 24, 10-19.	30.7	228
26	Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. <i>MBio</i> , 2018, 9, .	4.1	53
27	O-Acetylation is essential for functional antibody generation against <i>Staphylococcus aureus</i> capsular polysaccharide. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 81-84.	3.3	15
28	The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. <i>Vaccine</i> , 2018, 36, 6867-6874.	3.8	29
29	Distinct evolutionary patterns of <i>Neisseria meningitidis</i> serogroup B disease outbreaks at two universities in the USA. <i>Microbial Genomics</i> , 2018, 4, .	2.0	4
30	The role of vaccines in fighting antimicrobial resistance (AMR). <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2142-2149.	3.3	95
31	Preclinical Assessment of Glycoconjugate Vaccines. <i>ACS Symposium Series</i> , 2018, , 229-247.	0.5	1
32	MntC-Dependent Manganese Transport Is Essential for <i>Staphylococcus aureus</i> Oxidative Stress Resistance and Virulence. <i>MSphere</i> , 2018, 3, .	2.9	27
33	Safety, tolerability, and immunogenicity of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) in healthy Japanese adults. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-10.	3.3	8
34	Two Vaccines for <i>Staphylococcus aureus</i> Induce a B-Cell-Mediated Immune Response. <i>MSphere</i> , 2018, 3, .	2.9	16
35	<i>Escherichia coli</i> and <i>Staphylococcus aureus</i> : leading bacterial pathogens of healthcare associated infections and bacteremia in older-age populations. <i>Expert Review of Vaccines</i> , 2018, 17, 607-618.	4.4	84
36	From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 461-477.	4.4	46

#	ARTICLE	IF	CITATIONS
37	SA4Ag, a 4-antigen <i>Staphylococcus aureus</i> vaccine, rapidly induces high levels of bacteria-killing antibodies. <i>Vaccine</i> , 2017, 35, 1132-1139.	3.8	58
38	Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. <i>Vaccine</i> , 2017, 35, 1530-1537.	3.8	29
39	<i>Neisseria meningitidis</i> Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 216-223.	2.0	41
40	Safety, tolerability, and immunogenicity of a 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. <i>Vaccine</i> , 2017, 35, 375-384.	3.8	52
41	Meningococcal serogroup B vaccines: Estimating breadth of coverage. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 255-265.	3.3	48
42	A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. <i>New England Journal of Medicine</i> , 2017, 377, 2349-2362.	27.0	57
43	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen <i>Staphylococcus aureus</i> vaccine in healthy older adults: Results of a randomised trial. <i>Vaccine</i> , 2017, 35, 385-394.	3.8	43
44	Neutrophil killing of <i>Staphylococcus aureus</i> in diabetes, obesity and metabolic syndrome: a prospective cellular surveillance study. <i>Diabetology and Metabolic Syndrome</i> , 2017, 9, 76.	2.7	12
45	High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on <i>Staphylococcus aureus</i> Antigen MntC. <i>PLoS Pathogens</i> , 2016, 12, e1005908.	4.7	23
46	<i>Staphylococcus aureus</i> Clumping Factor A Remains a Viable Vaccine Target for Prevention of <i>S. aureus</i> Infection. <i>MBio</i> , 2016, 7, e00225.	4.1	11
47	<i>Staphylococcus aureus</i> : the current state of disease, pathophysiology and strategies for prevention. <i>Expert Review of Vaccines</i> , 2016, 15, 1373-1392.	4.4	116
48	The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease. <i>AAPS Journal</i> , 2016, 18, 1562-1575.	4.4	57
49	Safety and immunogenicity of a booster dose of a 3-antigen <i>Staphylococcus aureus</i> vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. <i>Journal of Infection</i> , 2016, 73, 437-454.	3.3	11
50	Differences between culture & non-culture confirmed invasive meningococci with a focus on factor H-binding protein distribution. <i>Journal of Infection</i> , 2016, 73, 63-70.	3.3	7
51	Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of <i>Neisseria meningitidis</i> by Use of Invasive and Carriage Isolate Collections. <i>Journal of Clinical Microbiology</i> , 2016, 54, 25-34.	3.9	27
52	Pan-genomic perspective on the evolution of the <i>Staphylococcus aureus</i> USA300 epidemic. <i>Microbial Genomics</i> , 2016, 2, e000058.	2.0	34
53	Letter to the editor: Importance of serum bactericidal activity for estimating the breadth of protection for new meningococcal vaccines. <i>Eurosurveillance</i> , 2016, 21, .	7.0	0
54	Demonstration of the preclinical correlate of protection for <i>Staphylococcus aureus</i> clumping factor A in a murine model of infection. <i>Vaccine</i> , 2015, 33, 5452-5457.	3.8	33

#	ARTICLE	IF	CITATIONS
55	Adult vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 150-155.	3.3	25
56	The Discovery and Development of a Novel Vaccine to Protect against <i>Neisseria meningitidis</i> Serogroup B Disease. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 5-13.	3.3	84
57	A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen <i>Staphylococcus aureus</i> vaccine (SA3Ag) in healthy adults. <i>Vaccine</i> , 2015, 33, 1846-1854.	3.8	56
58	Anti-infective vaccination in the 21st century—new horizons for personal and public health. <i>Current Opinion in Microbiology</i> , 2015, 27, 96-102.	5.1	13
59	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , 2015, 71, 43-52.	3.3	61
60	Evaluation of Approaches to Monitor <i>Staphylococcus aureus</i> Virulence Factor Expression during Human Disease. <i>PLoS ONE</i> , 2015, 10, e0116945.	2.5	41
61	Optimization of Molecular Approaches to Genogroup <i>Neisseria meningitidis</i> Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines. <i>PLoS ONE</i> , 2015, 10, e0132140.	2.5	18
62	Covering all the Bases: Preclinical Development of an Effective <i>Staphylococcus aureus</i> Vaccine. <i>Frontiers in Immunology</i> , 2014, 5, 109.	4.8	39
63	Immunofluorescence Microscopy for the Detection of Surface Antigens in Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA). <i>Methods in Molecular Biology</i> , 2014, 1085, 85-95.	0.9	8
64	Three-Dimensional Structure and Biophysical Characterization of <i>Staphylococcus aureus</i> Cell Surface Antigen—Manganese Transporter MntC. <i>Journal of Molecular Biology</i> , 2013, 425, 3429-3445.	4.2	54
65	A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. <i>Vaccine</i> , 2013, 31, 1569-1575.	3.8	73
66	Vaccine review: “ <i>Staphylococcus aureus</i> vaccines: Problems and prospects” <i>Vaccine</i> , 2013, 31, 2723-2730.	3.8	119
67	A novel approach to generate a recombinant toxoid vaccine against <i>Clostridium difficile</i> . <i>Microbiology (United Kingdom)</i> , 2013, 159, 1254-1266.	1.8	81
68	Potential impact of the bivalent rLP2086 vaccine on <i>Neisseria meningitidis</i> carriage and invasive serogroup B disease. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 471-479.	3.3	22
69	Role of Factor H Binding Protein in <i>Neisseria meningitidis</i> Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease. <i>Microbiology and Molecular Biology Reviews</i> , 2013, 77, 234-252.	6.6	96
70	Capsular polysaccharides are an important immune evasion mechanism for <i>Staphylococcus aureus</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 480-487.	3.3	103
71	A Multi-country Evaluation of <i>Neisseria meningitidis</i> Serogroup B Factor H Binding Proteins and Implications for Vaccine Coverage in Different Age Groups. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1096-1101.	2.0	36
72	Regulation of <i>Staphylococcus aureus</i> MntC Expression and Its Role in Response to Oxidative Stress. <i>PLoS ONE</i> , 2013, 8, e77874.	2.5	32

#	ARTICLE	IF	CITATIONS
73	Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against <i>S. aureus</i> and <i>Staphylococcus epidermidis</i> . <i>Journal of Infectious Diseases</i> , 2012, 205, 1688-1696.	4.0	88
74	Development of a multicomponent <i>Staphylococcus aureus</i> vaccine designed to counter multiple bacterial virulence factors. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1585-1594.	3.3	86
75	A Recombinant Clumping Factor A-Containing Vaccine Induces Functional Antibodies to <i>Staphylococcus aureus</i> That Are Not Observed after Natural Exposure. <i>Vaccine Journal</i> , 2012, 19, 1641-1650.	3.1	51
76	Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18-36 Months. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1061-1068.	2.0	57
77	Strategies for and advances in the development of <i>Staphylococcus aureus</i> prophylactic vaccines. <i>Expert Review of Vaccines</i> , 2011, 10, 695-708.	4.4	44
78	Prevalence and genetic diversity of candidate vaccine antigens among invasive <i>Neisseria meningitidis</i> isolates in the United States. <i>Vaccine</i> , 2011, 29, 4739-4744.	3.8	98
79	Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent <i>Neisseria meningitidis</i> Serogroup C Disease. <i>Hum Vaccin</i> , 2011, 7, 68-74.	2.4	43
80	Challenges for the evaluation of <i>Staphylococcus aureus</i> protein based vaccines: Monitoring antigenic diversity. <i>Hum Vaccin</i> , 2011, 7, 51-59.	2.4	40
81	New frontiers in meningococcal vaccines. <i>Expert Review of Vaccines</i> , 2011, 10, 617-634.	4.4	26
82	A fully human monoclonal antibody to <i>Staphylococcus aureus</i> iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. <i>Human Antibodies</i> , 2010, 19, 113-128.	1.5	48
83	Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. <i>Vaccine</i> , 2010, 28, 6086-6093.	3.8	182
84	Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. <i>Vaccine</i> , 2010, 28, 7667-7675.	3.8	18
85	Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B <i>Neisseria meningitidis</i> . <i>Journal of Infectious Diseases</i> , 2009, 200, 379-389.	4.0	180
86	Serologic Assay To Quantify Human Immunoglobulin G Antibodies to the <i>Staphylococcus aureus</i> Iron Surface Determinant B Antigen. <i>Vaccine Journal</i> , 2009, 16, 739-748.	3.1	12
87	<i>Staphylococcus aureus</i> capsule type 8 antibodies provide inconsistent efficacy in murine Models of staphylococcal infection. <i>Hum Vaccin</i> , 2009, 5, 254-263.	2.4	24
88	Selection and Characterization of Murine Monoclonal Antibodies to <i>Staphylococcus aureus</i> Iron-Regulated Surface Determinant B with Functional Activity In Vitro and In Vivo. <i>Vaccine Journal</i> , 2009, 16, 1095-1104.	3.1	39
89	Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by <i>Staphylococcus aureus</i> : Implications for vaccine design. <i>Vaccine</i> , 2009, 27, 3276-3280.	3.8	38
90	Detection of LP2086 on the cell surface of <i>Neisseria meningitidis</i> and its accessibility in the presence of serogroup B capsular polysaccharide. <i>Vaccine</i> , 2009, 27, 3417-3421.	3.8	68

#	ARTICLE	IF	CITATIONS
91	A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model. <i>Infection and Immunity</i> , 2006, 74, 2215-2223.	2.2	233